POST-TRANSCRIPTIONAL REGULATION OF C-MYC MRNA
POST-TRANSCRIPTIONAL REGULATION OF C-MYC MRNA
批准号:
3306634
负责人:
William M Lee
金额:
$19.68万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-05-01 至 1996-04-30
关键词:
cell differentiation cell free system cell type cycloheximide frameshift mutation gene expression genetic regulatory element laboratory mouse messenger RNA myoblasts neoplastic transformation nucleic acid sequence oncogenes point mutation posttranscriptional RNA processing protein degradation transfection
中文摘要
调控的C-myc基因表达是细胞的重要决定因素
增殖和分化,并避免肿瘤细胞行为。
调控通常发生在信使核糖核酸水平,取决于标记的
信使核糖核酸的不稳定,因为它的快速和频繁的
转录后。初步研究表明,C2小鼠成肌细胞
表达丰富的c-myc信使核糖核酸,该信使核糖核酸周转迅速。
依赖于C末端蛋白质编码序列的翻译。
C2细胞的分化伴随着c-myc mRNA水平的下降,
这是由于加速的营业额,这也取决于翻译
C-末端蛋白编码序列。这项提议的目标是
了解这些转录后调控c-myc的机制
表情。(I)界定翻译的结构决定因素--
依赖的c-myc基因的不稳定性将通过检测myc来实现
环己亚胺诱导的缺失和融合mRNAs,已被
被证明是由于药物抑制翻译和转录而使mRNA稳定
表明存在不稳定的myc基因。点移法和移标法的研究
突变体将表明核苷酸序列或编码的氨基酸
该元素的序列是不稳定的决定因素。一种类似的
将使用一种方法来描述以c-myc为靶点的结构元件
在C2分化过程中进行调控的基因。这项任务可以简化。
通过仅从放线菌亚胺中选择信息量最大的myc基因
在繁琐的C2分化试验中进行测试的研究,因为
初步研究表明,监管和监管的决定因素
不稳定可能也是一样的。(Ii)这些c-myc基因的鉴定
结构决定因素之后将描述它们的特征
意义。目前的混乱是由多样性造成的
到目前为止在c-myc mRNA中发现的可能的不稳定元件将是
通过确定哪个候选元素实际影响
通过指定其周转率来确定c-myc mRNA的稳态水平。这个
C-myc信使核糖核酸不稳定的翻译依赖机制
而差异化过程中的监管将通过检查其
在其他单元格类型中的使用。如果c-myc以外的mRNAs受
在分化过程中,它们的机制相同,可能共享myc mrna。
并在此基础上使用适当的搜索进行识别
或者克隆策略。(3)获得关于顺位代理主题的知识
调节c-myc mRNA水平将被用来表征交易
涉及的因素。一种方法是建立一个体外系统
C-myc mRNA的降解如实地概括了体内事件,并可以
用来表征和提纯这些因素。如果一个核苷酸序列
形成了调控的主题,确定了约束这一主题的因素
Sequence提供了另一种方法。这些研究有望揭示各种因素
参与调节细胞信使核糖核酸的周转,并披露
转录后c-myc基因调控的分子基础
细胞对生长和分化的正常反应的要素
刺激物。
英文摘要
Regulated C-myc gene expression is an important determinant of cell
proliferation and differentiation and averts neoplastic cell behavior.
Regulation usually occurs at the mRNA level, depends on the marked
instability of the mRNA for its rapidity and is frequently
post-transcriptional. Preliminary studies show that C2 murine myoblasts
express abundant c-myc mRNA and that the turnover of this mRNA is rapid and
depends on translation of C-terminal protein-coding sequences.
Differentiation of C2 cells is accompanied by a fall in c-myc mRNA levels,
which is due to accelerated turnover that also depends on translation of
C-terminal protein-coding sequences. The goal of this proposal is to
understand these post-transcriptional mechanisms regulating c-myc
expression. (I) Delineation of the structural determinant of translation-
dependent c-myc mRNA instability will be accomplished by testing myc
deletion and fusion mRNAs for induction by cycloheximide, which has been
shown to be due to mRNA stabilization by drug inhibition of translation and
is indicative of an unstable myc mRNA. Study of point and frame-shift
mutants will indicate if the nucleotide sequence or the encoded amino acid
sequence of this element is the instability determinant. A similar
approach will be used to delineate the structural element targeting c-myc
mRNA for regulation during C2 differentiation. This task may be simplified
by selecting only the most informative myc genes from the cycloheximide
studies for testing in the cumbersome C2 differentiation assay, since
preliminary studies indicate that the determinants of regulation and
instability may be the same. (II) Identification of these c-myc mRNA
structural determinants will be followed by characterization of their
significance. The current confusion resulting from the multiplicity of
putative destabilizing elements identified in c-myc mRNA to date will be
resolved by determining which candidate element actually influences the
steady-state level of c-myc mRNA by specifying its rate of turnover. The
prevalence of translation-dependent mechanisms for c-myc mRNA instability
and regulation during differentiation will be determined by examining their
usage in other cell types. If mRNAs other than c-myc are regulated by the
same mechanism during differentiation, they may share the myc mRNA
regulatory motif and be identifiable on this basis using appropriate search
or cloning strategies. (III) Knowledge gained about the cis-acting motifs
regulating c-myc mRNA levels will be used to characterize the transacting
factors involved. One approach will be to establish an in vitro system of
c-myc mRNA degradation that faithfully recapitulates in vivo events and can
be used to characterize and purify these factors. If a nucleotide sequence
forms the regulatory motif, identification of factors that bind this
sequence offers another approach. These studies promise to reveal factors
involved in the regulation of cellular mRNA turnover and to disclose the
molecular basis of post-transcriptional c-myc mRNA regulation, a key
element of the cell's normal response to growth and differentiation
stimuli.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:8141217
-
项目类别:
-
资助金额:$34.17万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:8730129
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:7932256
-
项目类别:
-
资助金额:$49.66万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
-
批准号:7591876
-
项目类别:
-
资助金额:$24.52万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
-
批准号:8330954
-
项目类别:
-
资助金额:$24.76万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
Hepatitis B Research Network Clinical Centers
-
批准号:9321421
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
-
批准号:7693775
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
-
批准号:8132960
-
项目类别:
-
资助金额:$25.97万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
-
批准号:7928729
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:8330285
-
项目类别:
-
资助金额:$14.69万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:7693832
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:8545814
-
项目类别:
-
资助金额:$24.44万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
-
批准号:7578376
-
项目类别:
-
资助金额:$16.19万
-
财政年份:2008
-
负责人:William M Lee
-
依托单位:
HALT-C TRIAL
-
批准号:7606312
-
项目类别:
-
资助金额:$1.73万
-
财政年份:2007
-
负责人:William M Lee
-
依托单位:
HALT-C TRIAL
-
批准号:7377603
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2006
-
负责人:William M Lee
-
依托单位:
HALT-C TRIAL
-
批准号:7206002
-
项目类别:
-
资助金额:$18.3万
-
财政年份:2005
-
负责人:William M Lee
-
依托单位:
HALT-C Trial
-
批准号:6975056
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2004
-
负责人:William M Lee
-
依托单位:
Transgenic Mice as Models for Antivascular Therapy
-
批准号:6751617
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2003
-
负责人:William M Lee
-
依托单位:
Transgenic Mice as Models for Antivascular Therapy
-
批准号:6588184
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2003
-
负责人:William M Lee
-
依托单位:
Transgenic Mice as Models for Antivascular Therapy
-
批准号:6914443
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2003
-
负责人:William M Lee
-
依托单位:
海外基金